|
07.01.2025 13:16:02
|
Orna Therapeutics, Vertex Pharma Enter Three-year Research Collaboration - Quick Facts
(RTTNews) - Orna Therapeutics, through its subsidiary ReNAgade Therapeutics, announced a three-year strategic research collaboration with Vertex Pharmaceuticals (VRTX) to utilize Orna's proprietary LNP delivery solutions to enhance Vertex's efforts in developing next generation gene editing therapies for patients with Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia.
Orna will receive upfront payments of $65 million, including an investment in the form of a convertible note, and is eligible to receive up to $635 million based upon the achievement of specified pre-clinical, research, development, regulatory and commercial milestones related to SCD/TDT products. Also, Orna is eligible to receive up to $365 million in additional option fees and milestones per product for up to ten additional products if Vertex options rights in additional indications. Vertex is funding the three-year research collaboration.
For More Such Health News, visit rttnews.com.
Nachrichten zu Vertex Pharmaceuticals Inc.
Analysen zu Vertex Pharmaceuticals Inc.
Im BX Morningcall werden folgende Aktien analysiert und erklärt:
✅ LPL Finance
✅ Blackstone
✅ Ares Management
👉🏽 https://bxplus.ch/bx-musterportfolio/
Inside Trading & Investment
Mini-Futures auf SMI
Inside Fonds
Aktien in diesem Artikel
| Vertex Pharmaceuticals Inc. | 383.68 | -6.19% |
|
Meistgelesene Nachrichten
Top-Rankings
Börse aktuell - Live Ticker
SMI geht im Plus ins Wochenende -- DAX schliesst nach Rekordhoch über 21'500-Punkte-Marke etwas tiefer -- Hang Seng legt letztlich kräftig zuDer heimische Aktienmarkt zeigte sich am Freitag etwas höher, während der deutsche Leitindex nach neuen Rekorden ins Minus drehte. Die US-Börsen notieren schwächer. Die asiatischen Indizes zeigten sich zum Wochenausklang überwiegend freundlich.
finanzen.net News
| Datum | Titel |
|---|---|
|
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
|
{{ARTIKEL.NEWS.BODY.TITEL}} |